Related Experiment Video
Updated: Apr 29, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
STAT1 regulates MD-2 expression in monocytes of sepsis via miR-30a
Yanhong Wang1, Tiehua Li, Benquan Wu
1Department of Medical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, China.
Abstract:
Sepsis is a major cause of morbidity and mortality in critically ill patients. MD-2 is a 25-kDa lipopolysaccharide (LPS)-binding protein that forms a heterodimer with TLR42, but its regulation in sepsis is not clear. This study aims to investigate the molecular mechanism of regulation of MD-2. Inflammation cytokines in monocytes were analyzed by real-time RT-PCR and ELISA, and it was found that IL-10 was elevated significantly in the monocytes with LPS treatment. And then, when the cells were treated with IL-10, STAT1 was activated in the monocytes using Western blotting. It was also found that STAT1 could enhance MD-2 expression on transcriptional and posttranscriptional levels. Finally, miR-30a was predicted to the molecule that may regulate STAT1 expression. It was verified that STAT1 was a new target gene of miR-30a. miR-30a could inhibit IL-10-induced cytokine release by targeting STAT1-MD-2 in monocytes. In conclusion, this study for the first time demonstrated that miR-30a inhibits MD-2 expression by targeting of STAT1 in human monocytes.
Insights
MicroRNA-30a (miR-30a) inhibits Myeloid differentiation factor 2 (MD-2) expression in human monocytes by targeting STAT1. This discovery offers new insights into sepsis regulation and potential therapeutic targets.
Area of Science:
- Immunology
- Molecular Biology
- Critical Care Medicine
Background:
- Sepsis is a leading cause of death in critically ill patients.
- Myeloid differentiation factor 2 (MD-2) is crucial in the Toll-like receptor 4 (TLR4) pathway but its regulation in sepsis is unclear.
- Understanding MD-2 regulation is vital for developing effective sepsis treatments.
Purpose of the Study:
- To elucidate the molecular mechanisms regulating MD-2 expression in sepsis.
- To investigate the role of Interleukin-10 (IL-10) and Signal transducer and activator of transcription 1 (STAT1) in MD-2 regulation.
- To identify microRNAs involved in the STAT1-MD-2 pathway.
Main Methods:
- Real-time RT-PCR and ELISA were used to analyze cytokine expression in monocytes.
- Western blotting was employed to detect STAT1 activation.
- Bioinformatic prediction and experimental validation identified miR-30a as a regulator of STAT1.
Main Results:
- Lipopolysaccharide (LPS) treatment significantly elevated IL-10 levels in monocytes.
- IL-10 treatment activated STAT1, which enhanced MD-2 expression transcriptionally and posttranscriptionally.
- miR-30a was confirmed as a direct target of STAT1, inhibiting IL-10-induced cytokine release by targeting the STAT1-MD-2 axis.
Conclusions:
- This study reveals that miR-30a inhibits MD-2 expression by targeting STAT1 in human monocytes.
- The miR-30a/STAT1/MD-2 pathway represents a novel regulatory mechanism in sepsis.
- Targeting this pathway could offer new therapeutic strategies for sepsis management.
Related Concept Videos
Master Transcription Regulators
Bacterial Meningitis II: Pathophysiology
MicroRNAs

